Searchable abstracts of presentations at key conferences on calcified tissues

ba0001cu1.2 | Clinical Update 1 | ECTS2013

Management of osteoporosis in pre-menopausal women

Walsh Jennifer

Low bone density in younger women is often due to underlying conditions such as eating disorders, premature ovarian failure or glucocorticoid treatment. It may also be due to genetically low peak bone mass.In general, absolute fracture risk in young women is low, even in the context of low bone density. Management should begin with treatment of underlying causes where possible, and lifestyle modification where appropriate.The evide...

ba0001w1.3 | Fat and bone | ECTS2013

Effects of fat on bone: location and age matter

Walsh Jennifer

The epidemiological evidence is clear that higher body weight is protective against most fractures in adults. However, the same may not be true in children. Understanding the mechanisms of interaction of fat and bone may give useful insights into underlying physiology for prevention of fracture.In general, higher body weight in adults is associated with higher bone mineral density and is protective against fracture, but may be associated with an increase...

ba0003pp209 | Muscle, physical activity and bone | ECTS2014

Does bone density, bone strength, sarcopenia or dynapenia explain greater risk of fracture in obesity?

Evans Amy , Eastell Richard , Walsh Jennifer

Obesity is associated with greater risk of proximal humerus and ankle fracture, despite greater areal BMD (aBMD). We aimed to investigate whether greater risk of some fractures in obesity was due to skeletal or non-skeletal determinants. 100 individually-matched pairs of normal weight (NW) (18.5–24.9 kg/m2) and obese (OB) (BMI >30 kg/m2) individuals, aged 25–40 and 55–75 years underwent DXA to determine hip and lumbar spine aBMD, whole ...

ba0005p454 | Other diseases of bone and mineral metabolism | ECTS2016

Bone mineral density and vascular calcification in obesity

Bouquegneau Antoine , Walsh Jennifer , Evans Amy , Paggiosi Margaret , Eastell Richard

Background: The presence of vascular calcification (VC) is a predictive factor for the development of cardiovascular diseases, especially in the obese population. VC has also been inversely associated with bone mineral density (BMD) but the results have been inconsistent. The main aim of this study was to evaluate the associations between VC, obesity and volumetric BMD (vBMD).Methods: We studied 148 healthy men and women, aged 55–75 years, divided i...

ba0003oc6.5 | Osteoporosis treatment and the effects of physical activity | ECTS2014

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal women with rsteoporosis: The TRIO study

Gossiel Fatma , Hoyle Christopher , McCloskey Eugene , Walsh Jennifer , Peel Nicola , Eastell Richard

Bisphosphonates are used to treat bone disease characterised by increased bone resorption by inhibiting the activity of mature osteoclasts, resulting in decreased bone turnover. Bisphosphonates may reduce the population of osteoclast precursor cells (OPCs). Our aims were to investigate the effect of bisphosphonates on i) OPCs and ii) bone turnover in postmenopausal women with osteoporosis compared with healthy premenopausal women. Participants were 62 postmenopausal women (mea...

ba0003pp306 | Osteoporosis: treatment | ECTS2014

The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study

Gossiel Fatma , Naylor Kim , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Paggiosi Margaret , Eastell Richard

Treatment of postmenopausal osteoporosis with bisphosphonates reduces bone resorption and formation. Sclerostin, an osteocyte regulator of bone formation may be involved in these changes. Some studies have reported an increase in sclerostin associated with bisphosphonate treatment while others have reported a decrease. The aims were to determine the effect of bisphosphonates on i) circulating sclerostin and ii) PINP in postmenopausal women with osteoporosis. We studied 92 post...

ba0003pp330 | Osteoporosis: treatment | ECTS2014

Determinants of bone turnover marker response to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

Naylor Kim , Paggiosi Margaret , Gossiel Fatma , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Eastell Richard

Three oral bisphosphonates ibandronate, alendronate, and risedronate are commonly used for the treatment of osteoporosis but they have not previously been compared in the same study. Our aim was to identify determinants of change in bone turnover markers (BTM) in response to these bisphosphonates in a 2-year randomised parallel group trial. We recruited 171 postmenopausal osteoporotic women (<85 years) who were randomised to receive ibandronate (150 mg monthly), alendronat...

ba0005oc3.4 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

The response of fibroblast growth factor-23 to teriparatide in postmenopausal osteoporosis

Gossiel Fatma , McCloskey Eugene , Walsh Jennifer , Naylor Kim , Peel Nicola , Eastell Richard

FGF-23 is a phosphate regulating hormone and its production may be stimulated by circulating levels of 1,25-dihydroxyvitamin D (1,25-(OH)2D). Teriparatide administration increases levels of 1,25-(OH)2D, however it is unclear whether this mediates changes in FGF-23 levels. The aims were i) to determine the effect of teriparatide treatment on circulating levels of FGF-23 and 1,25-(OH)2D and ii) to describe the time course of effect in postmenopau...

ba0005p97 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2016

Vitamin D therapy: the effects of race, skin colour and genotype

Sujatha Jaya , Kothandapani Gopal , Evans Lucy , Fatma Gossiel , Walsh Jennifer , Eastell Richard , Bishop Nick

Background: It is well established that Asians have lower levels of vitamin D (25OHD) when compared to Caucasians. Vitamin D binding protein (DBP) levels are also lower in some races than in Caucasians.Objectives: i) To find out whether DBP is lower in Asians; ii) To find out whether free 25OHD is lower in Asians; iii) To find out whether PTH is increased in Asians and interpret this in relation to 25OHD levels and iv) To find out whether the increment i...